XNCR News and Press, Xencor Inc. From 03/31/19

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year tests of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech...

Xencor, Inc. (XNCR) Q4 2018 Results Earnings Conference Call February 25, 2019, 04:30 PM ET Company Participants Charles Liles - Associate Director and Head of Corporate Communications and IR Bassil Dahiyat - President and CEO Paul Foster - SVP and Chief Medical Officer John Ku...

Xencor (NASDAQ: XNCR ) Q4 results ($M): Revenues: 11.6 (-61.6%). Drop due to milestone payments from Alexion last year. More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Xencor (NASDAQ: XNCR ): Q4 GAAP EPS of -$0.32 beats by $0.17 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

MONROVIA, Calif. , Feb. 25, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and ...